HC Wainwright set a $38.00 price target on Stemline Therapeutics (NASDAQ:STML) in a report released on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
“Our 12-month price target is derived from a discounted cash flow-based asset value of $1.2B for 15% discount rate and 2% terminal growth rate. Probabilities of success ascribed to SL-401 and SL-701 are 90% and 45%, respectively. Investment risks include: (1) failure of drug candidates in clinical trials; (2) failure of drug candidates to secure regulatory approval; (3) failure of drug candidates to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential dilution risk.”,” the firm’s analyst wrote.
Several other analysts have also issued reports on STML. BidaskClub raised Stemline Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 14th. ValuEngine raised Stemline Therapeutics from a hold rating to a buy rating in a report on Tuesday, August 14th. Zacks Investment Research raised Stemline Therapeutics from a sell rating to a hold rating in a report on Thursday, August 16th. Wedbush reissued an outperform rating and set a $22.00 price target on shares of Stemline Therapeutics in a report on Monday, November 12th. Finally, Roth Capital set a $33.00 price target on Stemline Therapeutics and gave the company a buy rating in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $26.32.
NASDAQ:STML traded down $0.19 during mid-day trading on Friday, hitting $9.98. 247,177 shares of the company traded hands, compared to its average volume of 411,752. Stemline Therapeutics has a one year low of $9.65 and a one year high of $20.55.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). Equities research analysts predict that Stemline Therapeutics will post -2.8 EPS for the current year.
In other news, COO Kenneth Hoberman sold 26,296 shares of the company’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $11.85, for a total value of $311,607.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 14.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in STML. BlueMountain Capital Management LLC bought a new position in shares of Stemline Therapeutics in the second quarter worth about $137,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Stemline Therapeutics in the second quarter worth about $166,000. MetLife Investment Advisors LLC lifted its position in shares of Stemline Therapeutics by 54.6% in the third quarter. MetLife Investment Advisors LLC now owns 18,474 shares of the biopharmaceutical company’s stock worth $307,000 after buying an additional 6,527 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Stemline Therapeutics by 97.8% in the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 10,159 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Stemline Therapeutics in the second quarter worth about $398,000. 64.20% of the stock is owned by hedge funds and other institutional investors.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Featured Article: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.